reading difficulties, and visual hallucinations, are relatively common. Detailed ophthalmological examinations also suggest a loss of visual acuity, contrast sensitivity, color discrimination, and motion perception and a reduced electroretinogram response. [5] [6] [7] [8] [9] [10] [11] The cellular and molecular mechanisms that lead to vision impairment in PD are still unclear and little information is known about how PD affects the retina.
The pathology of PD is characterized by the presence of pathological deposits of a-synuclein throughout the central (CNS) 12, 13 and peripheral nervous systems (PNS), [14] [15] [16] [17] [18] causing parkinsonism attributed to the massive and irreversible loss of dopaminergic neurons in the SNpc and eventual cognitive dysfunction attributed to its effects on the cerebral cortex. The pathological a-synuclein deposits, contained within Lewy bodies and Lewy neurites, are associated with abnormally phosphorylated a-synuclein (p-syn). 19, 20 a-synuclein is a small and highly conserved protein of 140 amino acids that is enriched in presynaptic terminals in different neural regions. 21, 22 Its physiological functions remain unclear, but some studies suggest a role in the regulation of synaptic vesicle formation and neurotransmitter release. 22, 23 Whereas the native, unphosphorylated conformation is present in several retinal cell types, 21, 24 the phosphorylation of a-synuclein at serine 129 can be used as a specific marker of CNS synucleinopathy. 25, 26 Because of the importance of p-syn in the possible spreading of the disease and findings of its presence in the PNS in PD, 4, 16 this study analyzed Lewy-type asynucleinopathy (LTS) in the retina of autopsied PD subjects. Additionally, subjects that showed no clinical signs of parkinsonism or dementia, but had LTS in the brain (incidental Lewy body disease [ILBD] subjects), were also studied as possible prodromal disease. We aimed to characterize which cells and structures accumulate p-syn and to study whether the amount of psyn in the retina was related to p-syn load in the brain. These results could lead to a better understanding of disease spread and help in the search for an accessible diagnostic and progression biomarker for PD and other synucleinopathies.
Materials and Methods

Source of Human Subjects
Human retina samples from 6 controls, 4 subjects with ILBD, and 9 PD subjects were obtained postmortem from volunteer donors in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND)/ Banner Sun Health Research Institute Brain and Body Donation Program (BBDP; www.brainandbodydonationprogram.org). 27 All procedures were conducted in accord with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. All subjects provided signed written informed consent approved by an institutional review board.
Clinical and Neuropathological Characterization of Human Subjects
Individuals included in the study were clinically characterized using standard tests that analyzed neurological, cognitive, and movement disorder components, and private medical records were reviewed and abstracted for each subject as previously described. 27 These included the UPDRS. Standardized neuropathological examinations determined the Unified Staging System for Lewy Body disorders histopathological stage as previously described. 28 The diagnosis of PD is clinicopathological: The subjects must have had motor parkinsonism as well as Lewy body pathology and pigmented neuron loss in the SN at autopsy. 29 
Immunohistochemistry
After enucleation, eyeballs were immediately fixed in cold neutral-buffered 10% formalin for 48 to 72 hours. They were washed in 0.1 M of sodium phosphate buffer (pH 7.4) and sequentially cryoprotected in 15%, 20%, and 30% sucrose. Cornea, lens, and vitreous body were removed and eyecups were processed and cut in eight pieces. 30 Some portions were used as whole-mount retinas, for which they were subjected to a freeze-thaw cycle to improve antibody penetration. Others were cut on a cryostat to obtain vertical sections of 14 lm.
Immunohistochemistry using the di-aminobenzidine method was performed on flat whole-mount retinas to specifically stain p-syn, following a previously published protocol. 30 A rabbit antibody against asynuclein phosphorylated at serine 129 was used, kindly provided by Dr. Haruhiko Akiyama, at a 1:1,000 dilution. Its specificity has been demonstrated in other studies. 14, 25, 26 Samples were flat-mounted in glycerol/phosphate buffer (PB) 0.1 M (1:1) with the ganglion cell layer side up. Images were taken with a Leica DMR microscope (Leica Microsystems, Wetzlar, Germany). Drawings were made using camera lucida.
Fluorescence immunohistochemistry was performed in vertical sections and in whole-mount retinas. First, transverse sections were washed with PB 0.1 M and incubated overnight at room temperature in either the p-syn antibody or a rabbit polyclonal primary antibody against native a-synuclein (Catalog No. sc-7011; Santa Cruz Biotechnology, Dallas, TX) diluted 1:100 in 0.1 M PB plus 0.5% Triton X-100. Next 
covered with a coverslip. In whole-mount retinas, the incubation times were longer: 3 days for the primary antibodies, which included, for some sections, double staining with rabbit polyclonal anti-RBPMS (RNAbinding protein with multiple splicing), diluted 1:1,000, and 2 days for the secondary antibody (Alexa Fluor 555 donkey antirabbit IgG at a 1:100 dilution).
The RBPMS antibody was a generous gift from Dr. Nicholas Brecha and specifically recognizes retinal ganglion cells. 31 Retinas were flat-mounted in Citifluor (Citifluor Ltd, London, UK) with the ganglion cell layer side up. Fluorescence images were taken using a TCS SP2 confocal laser-scanning microscope (Leica Microsystems).
Lewy-Type Synucleinopathy Density
Score in Retina and Brain p-syn-stained whole-mount retinas and brains were semiquantitatively rated for the density of p-syn immunoreactive cellular structures by reviewers who were blinded to clinical diagnosis. In brain tissue, the load of p-syn immunoreactivity was assessed semiquantitatively in 10 standard brain regions, and their summation represents the final brain p-syn load score. 12 In retina, the number of stained neuronal perikarya in the nasal-inferior quadrant was manually counted. The density of stained axons and dendrites was assessed using a semiquantitative 0 to 3 scale, where 0 revealed no p-syn and 3 represented high densities of p-syn. The final retina score was calculated as the summation of the separate scores for perikarya as well as axons and dendrites (Table 1) .
Statistical Analysis
All studied subjects were included in correlation analyses to compare retina and brain Lewy-type synucleinopathy density score; retina Lewy-type synucleinopathy density score and brain pathology stage; and retina Lewy-type synucleinopathy density score and motor UPDRS score. The Lewy-type synucleinopathy score was based on the number and amount of p-syn immunoreactive structures in standard regions of the brain and retina. For the retinal analysis, only one eye per subject was used, using always the nasal inferior quadrant. SigmaPlot (Systat Software, Inc., San Jose, CA) and GraphPad Prism software (version 6; GraphPad Software Inc., San Diego, CA) were used to analyze the data. All the correlations were performed by a two-tailed Spearman correlation test, and all the individuals were considered for the study. To compare LTS scores between groups (control, ILBD, and PD), the nonparametric Kruskal-Wallis analysis of variance was performed and followed by the post-hoc Dunn's multiple comparison test. The significance level was set at P < 0.05.
Results
Age, clinical diagnosis, neuropathological diagnosis, unified LTS stage, and LTS density scores in brain and retina, as well as the motor UPDRS scores of analyzed subjects are shown in Table 1 .
Native a-synuclein (a-syn) is ubiquitous in the CNS and it is present in all retinal layers and cells, although predominantly in photoreceptor outer segments, amacrine cells, and the inner plexiform layer. No immunostaining differences were found between PD and control subjects: a-syn was present in the same cell types and with a similar intensity in both groups (Fig.  1A,B) . By contrast, p-syn, a specific pathological marker of synucleinopathies, is present in retinas of PD subjects and 3 of 4 ILBD subjects and it is absent in all the 6 control retinas. Figures 1, 2 and 3 show representative photomicrographs of immunohistochemical staining for p-syn in retina of PD and ILBD subjects. p-syn deposits were found as axonal fibers and dendrites and/or neuronal perikarya (Figs. 1, 2, and 3). Cells containing p-syn had different morphologies, soma sizes (ranging from 15 to 30 lm), dendritic lengths (ranging from 570 to 1,620 lm), and receptive fields. They had their cell bodies located in the ganglion cell layer, near the inner surface of the retina, with major dendritic ramifications in retinal strata S3 and S4 of the inner plexiform layer (Fig. 1C-F) .
Along with normal-appearing dendrites and cell bodies, some aberrant structures were also detected in the ganglion cell layer of PD subjects. In Figure 2 curly dendrites, abnormal and twisted structures, swollen dendrites, and intracytoplasmic accumulations of p-syn can be observed. These dendritic alterations are a characteristic mark of cell pathology, degeneration, or dysfunction, including synucleinopathy. Some of the immunoreactive cell bodies were clearly associated with immunoreactive axons (Fig. 1C,D) . Other long fibers, putatively axons, that crossed the retina but did not visibly emerge from any cell body, were also found and can be seen in Figure 2 . Some of these axons had normal morphology (Fig. 2E ), but others had abnormal beading and swollen segments (Fig. 2F) . All of these p-syn immuoreactive morphological alterations were always found within the ganglion cell layer, and the immunoreactive perikarya were all ganglion cells, as shown by double staining with RBPMS, a ganglion cell marker (Fig. 2G-I) .
Retinas with positive staining for p-syn had either all or several types of these stained structures present, at relatively sparse densities from the center to periphery. The neural perikaryal staining shown in Figure 3 is condensed into defined inclusions in the cell cytoplasm, resembling classic brain Lewy bodies. p-synpositive Lewy body-like structures in the PD retinas were more frequent and prevalent than p-syn-positive 
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complete cell or neurites. We also observed p-syn immunoreactive dotted neurites with typical dystrophic Lewy neurite morphology. This is the first time that p-syn Lewy-like bodies and neurites have been described in retina of PD subjects. The described p-syn-positive structures were observed in the retinas of all 9 PD subjects and in 3 of 4 subjects with ILBD. p-syn immunoreactivity was absent in the brain and retina of all 6 clinicopathologically diagnosed controls.
Retina and brain LTS scores differed between the three clinicopathological groups, being statistically significant between controls and PD (P < 0.001). Spearman's correlation test, done considering only the affected groups (ILBD and PD), revealed a strong positive correlation between LTS density score in brain and retina (Spearman's q 5 0.7861; P < 0.005; Fig. 4 ). Retinal LTS density score also correlated with brain pathology stage (Spearman's q 5 0.5833; P < 0.05) and with the motor UPDRS score (Spearman's q 5 0.6661; P < 0.05), suggesting that pathology progression is related in both tissues and that retinal analysis may give information about brain disease stage and severity. 1319
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Discussion
Possibly attributed to the difficulty in obtaining high-quality postmortem human retinas, there are very few studies about retinal changes at a cellular level in PD subjects. The aim of the study was to analyze the presence of p-syn, one of the main hallmarks of PD, in postmortem retinal tissue of control and PD donors and to compare it with clinical and brain neuropathological features.
Although PD can be clinically diagnosed with reasonable accuracy in subjects with long-standing disease, in those with clinical symptoms of less than 5 years' duration, diagnostic accuracy may be as low as 53%. 32 The importance of early diagnosis, and the need to monitor the effects of therapy, makes necessary the identification of new biomarkers for PD. Because of the close relationship of the eye with the brain, their common embryonic nature, and the ability to examine the eyes and retina of living subjects with 
imaging techniques, the retina could be a candidate biomarker tissue for neurodegenerative diseases. As a part of the CNS, the retina reflects some of the pathological alterations of brain-predominant neurodegenerative diseases like Alzheimer's disease (AD), PD, and Huntington's disease. 33 Visual dysfunction and retinal changes in PD have been widely reported. 5, 6 Patients suffering from PD have functional visual alterations such as reduced electroretinogram (ERG) responses and prolonged latency in visual evoked potentials. [33] [34] [35] [36] They also show a loss in contrast sensitivity and color perception abnormalities. 11, 33, 34, 37, 38 In PD animal models, loss of dopaminergic amacrine cells, together with reduced ERG scotopic a-and b-wave amplitudes, have been demonstrated. 33, 39, 40 In addition, using the optical coherence tomography (OCT) imaging technique in patients in vivo, some researchers have shown a thinning of the inner retinal layers: the ganglion cell layer, inner plexiform layer, and inner nuclear layer, 41-43 although there is some controversy about this issue and other studies show no difference in this aspect. 44 All these studies seem to indicate that the retina becomes involved in PD, although it remains unknown to what extent.
This study establishes the presence of p-syn within retinal ganglion cells, the major retinal projection neurons, as demonstrated by double staining with RBPMS. This accumulation is relatively sparse, with relatively few ganglion cells affected. The exact type of ganglion cell affected is still undetermined, but they seem to be different ganglion cell types based on their different morphologies. This suggests that the p-syn accumulation may not be cell-type specific. Supporting a localization exclusively to ganglion cells, retinal amacrine cells, including dopaminergic amacrine cells, did not have any p-syn immunoreactivity.
This study is the first to demonstrate p-syn immunoreactive retinal structures similar to brain Lewy bodies and neurites. Previous research using antibodies against a-syn in thin paraffin sections stated that no pathological a-syn immunoreactivity could be found in the retina and lens of PD patients 45 or in any part of the ocular globe in AD. 46 Differences with our study may be attributed to our use of antibodies against p-syn rather than unmodified a-syn, and our use of retinal whole mounts rather than thin paraffin sections. The relatively small number of p-syn-positive structures may be difficult to detect in the small tissue volumes available in paraffin sections. Despite these differences between studies, further investigations of the eye in PD are desirable, given that it is known that ocular structures are involved in the pathology of several neurodegenerative diseases. 33, 47 For example, tears, 48, 49 lens, 50,51 cornea, 52 and retina 53 have already been investigated and proposed as sources for possible PD biomarkers.
Additionally, in this study it was demonstrated that the accumulation of p-syn in the retina specifically cosegregated with subjects that had LTS in the brain. 
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This included all 9 PD subjects as well as 3 of the 4 ILBD subjects. No study has previously found p-syn accumulation in ILBD, and its presence, even preceding clinical signs of parkinsonism or dementia, could be extremely important as a potential biomarker for neuroprotective prevention trials. Specificity was excellent given that none of the 6 controls had p-syn in the retina. Additionally, there was a strong correlation between brain and retina LTS density scores and between retinal LTS density and clinical disease. The major limitation of this study is the small number of subjects in each group. However, this is offset, to some degree, by the fact that all subjects in the study had autopsy confirmation of disease. The fact that all 9 PD subjects and 3 of 4 ILBD subjects had retinal LTS, and that none of the 6 controls had retinal LTS, suggests that sensitivity and specificity may be very high, even preceding clinical signs of PD become present. The positive correlation between LTS density in the retina and brains of PD subjects and its correlation with motor scores and disease stage suggests that the progression of the disease is related in both tissues. Because of that, the retina could act as a window into the brain pathology and serve as a biomarker of brain PD pathology. In fact, researchers have been able to detect p-syn/ GFP (green fluorescent protein) aggregates in the retina of a PD mouse model (transgenic mice expressing a fused a-syn/GFP gene under the PDGFb promoter [PDNG78 line]) using a noninvasive in vivo retinal imaging microscope. 54 This technique allowed longitudinal evaluation of the same retinal areas over time.
We suggest that a methodology similar to that used by Price and colleagues could be used to evaluate the in vivo presence of synucleinopathy in the retinas of prodromal and symptomatic PD patients. As Price and colleagues have done in the mouse, retinas of living individuals could potentially be assessed using available and routine ophthalmological noninvasive imaging techniques like OCT, eye fundus, angiography, etc. These techniques allow to visualize the whole retina and to see retinal changes. To specifically mark LTS, development of 
